tradingkey.logo

Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook

ReutersJan 12, 2026 1:02 PM

- Bicara Therapeutics Inc BCAX.O:

  • BICARA THERAPEUTICS ANNOUNCES PHASE 3 OPTIMAL DOSE AND PROVIDES 2026 CORPORATE OUTLOOK

  • BICARA THERAPEUTICS - EXPECTS TO ACHIEVE SUBSTANTIAL ENROLLMENT IN FORTIFI-HN01 IN 2026 TO ENABLE INTERIM ANALYSIS IN MID-2027

  • BICARA THERAPEUTICS INC - ANTICIPATES MULTIPLE DATA READOUTS IN 2026 FOR FICERAFUSP ALFA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI